Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

The Reko Diq copper and gold project in Pakistan could generate $74B in free cash flow over the next 37 years, based on consensus long-term prices, Barrick Gold (NYSE:GOLD) Mark Bristow said ...

After two years of relatively muted investment activity, it seems that VCs are starting to pour capital into startups at pandemic-era levels once again. But a closer look shows that they aren’t ...

Shanghai is expected to invest 240 billion yuan ($32.74 billion) in major construction projects in 2025, according to the Shanghai Municipal Government Work Report delivered by Mayor Gong Zheng.

Bristol-Myers Squibb’s (BMS) largest shareholder has come out against the company’s planned merger with Celgene, putting the future of the deal in doubt. The $74 billion deal, announced in ...

The study was supported by the National Natural Science Foundation of China (grant #22107101), an investigator-initiated grant from Bristol Myers-Squibb — Celgene, the National Institute of ...

Revlimid, the big-selling multiple myeloma drug acquired in Bristol’s buyout of Celgene, will face a new ... in the first 9 months of 2024, but BMS expects an "additional step down” to $2 ...

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial Over the past 15 years, the landscape ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

To sign up for Becker's Pharmacy Report E-Newsletter or any of our other E-Newsletters, click here. If you are experiencing difficulty receiving our newsletters, you may need to whitelist our new ...

As a sweetener for shareholders ahead of the deal, BMS created a “contingent value right” for each share of Celgene, with each paying out $9 cash if three drugs get approved by the FDA in time ...